AOTMiT Transparency Council Meeting: Evaluation of drugs and drug programs and health policy

The agenda includes:

1 Prepare a position paper on the evaluation of the drug Kanuma (sebelipazum alfa) under the drug program "Treatment of patients with lysosomal acid lipase deficiency (ICD-10 E75.5 E75.6)".

2 Prepare a position paper on the evaluation of the drug Keytruda (pembrolizumabum) under the drug program "Treatment of patients with endometrial cancer (ICD-10: C54)".

3 Prepare a position paper on examining the appropriateness of issuing approvals for reimbursement of the foodstuff for special nutritional use Glycosade for the indication: glycogenosis and glycogenosis type Ia, Ib, III, IV, VI, IX, XI, III-VI-IX.

4 Prepare an opinion on the draft health policy program of the local government unit co-financed by the EU under the ESF "Regional Health Program - Prevention of cardiovascular diseases in oncology patients in the West Pomeranian region."

5 Prepare an opinion on the draft health policy program of the local government unit "Program for prevention and early detection of overweight and obesity among children in the municipality of Lubin for 2024-2027".

6 Prepare an opinion on the draft health policy program of the local government unit "Program of comprehensive therapy and rehabilitation of people aged 0-25 from the City of Zabrze".

7 Prepare an opinion on the continuation of the inclusion in reimbursement of medicinal products containing the active substance voriconazoleum in the indication: prevention of invasive fungal infections in high-risk patients with immunodeficiency syndromes.

Source: AOTMiT